Browse by category

Results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes, have revealed that people with severe obesity on the highest dose (12mg) lost on average 30% of their body weight over two years. In addition, at 80 weeks, all doses of retatrutide (4mg, 9mg and 12mg) met the primary and key secondary endpoints for obesity, delivering clinicall